Please assess the completion status of the following clinical trial:

Trial Title: Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient must be at least 18 years of age.~2. Culprit de novo lesion in a native coronary artery with significant stenosis (\>50% by visual estimate) eligible for stent implantation (no limitation on stent length)~3. Prolonged, continuous (≥ 20 min) chest pain despite nitrate and: (1) at least 1mm ST-segment elevation in at least 2 leads or reciprocal ST-segment depression ≥ 2 contiguous precordial leads, or (2) newly developed left bundle branch block~4. Symptoms \< 12 hours~5. The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.~Exclusion Criteria:~1. The patient has a known hypersensitivity or contraindication to any of the following medications:~   * Heparin~  * Aspirin~  * Both Clopidogrel and TIclopidine~  * Sirolimus, paclitaxel, ABT 578~  * Stainless steel and/or~  * Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled).~2. Systemic (intravenous) Sirolimus, paclitaxel or ABT-578 use within 12 months.~3. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.~4. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions.~5. Fibrinolytic therapy for current MI treatment~6. Previous coronary intervention on target vessel~7. Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).~8. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.~9. Previously documented LVEF \<30%.~10. Evident cardiogenic shock before randomization~11. Patients with left main stem stenosis (\>50% by visual estimate)~12. Severe calcification or tortuosity~13. Multi-vessel disease with non-culprit vessel requiring bypass surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endeavor (Type: EXPERIMENTAL): Zotarolimus-eluting stent
- Cypher (Type: ACTIVE_COMPARATOR): Sirolimus-eluting stent
- Taxus (Type: ACTIVE_COMPARATOR): Paclitaxel-eluting stent

Based on this trial design, predict the completion outcome and termination type (if applicable).